NO20093275L - 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase - Google Patents

1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase

Info

Publication number
NO20093275L
NO20093275L NO20093275A NO20093275A NO20093275L NO 20093275 L NO20093275 L NO 20093275L NO 20093275 A NO20093275 A NO 20093275A NO 20093275 A NO20093275 A NO 20093275A NO 20093275 L NO20093275 L NO 20093275L
Authority
NO
Norway
Prior art keywords
alkyl
dihydroimidazole
hydroxylase
inhibitors
enantiomers
Prior art date
Application number
NO20093275A
Other languages
English (en)
Norwegian (no)
Inventor
Patricio Manuel Vieira Araujo Soares Da Silva
David Alexander Learmonth
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20093275(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of NO20093275L publication Critical patent/NO20093275L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20093275A 2007-05-08 2009-11-03 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase NO20093275L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
NO20093275L true NO20093275L (no) 2010-02-04

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093275A NO20093275L (no) 2007-05-08 2009-11-03 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase

Country Status (30)

Country Link
US (5) US8481582B2 (el)
EP (1) EP2155731B1 (el)
JP (1) JP5559677B2 (el)
KR (1) KR101598482B1 (el)
CN (1) CN101687858B (el)
AR (2) AR066457A1 (el)
AT (1) ATE499367T1 (el)
AU (1) AU2008246443B2 (el)
BR (1) BRPI0811275B8 (el)
CA (1) CA2686387C (el)
CL (1) CL2008001321A1 (el)
CY (1) CY1111517T1 (el)
DE (1) DE602008005141D1 (el)
DK (1) DK2155731T3 (el)
ES (1) ES2360841T3 (el)
GB (1) GB0708818D0 (el)
HK (1) HK1142898A1 (el)
HR (1) HRP20110253T1 (el)
IL (1) IL201921A (el)
MX (1) MX2009012041A (el)
NO (1) NO20093275L (el)
NZ (1) NZ580962A (el)
PL (1) PL2155731T3 (el)
RS (1) RS51692B (el)
RU (1) RU2501796C2 (el)
SI (1) SI2155731T1 (el)
TW (1) TWI458722B (el)
UA (1) UA104844C2 (el)
WO (1) WO2008136695A1 (el)
ZA (1) ZA200908612B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP6075621B2 (ja) * 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
WO2013002660A2 (en) * 2011-06-29 2013-01-03 BIAL - PORTELA & Cª, S.A. Process
KR102259938B1 (ko) * 2012-11-14 2021-06-03 바이알 - 포르텔라 앤드 씨에이 에스에이 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190050A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
AR112804A1 (es) 2017-09-13 2019-12-11 Amgen Inc Compuestos de bisamida que activan el sarcómero y sus usos
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
RU2145321C1 (ru) 1994-04-26 2000-02-10 Синтекс (Ю.Эс.Эй) Инк. Производные бензоциклоалкилазолотиона
AR032711A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
ZA200908612B (en) 2010-11-24
CA2686387A1 (en) 2008-11-13
AR112789A2 (es) 2019-12-11
SI2155731T1 (sl) 2011-05-31
NZ580962A (en) 2012-05-25
MX2009012041A (es) 2010-02-18
US20170369478A1 (en) 2017-12-28
KR20100017546A (ko) 2010-02-16
US9630951B2 (en) 2017-04-25
JP2010526136A (ja) 2010-07-29
RS51692B (en) 2011-10-31
BRPI0811275B1 (pt) 2020-01-07
PL2155731T3 (pl) 2011-07-29
HRP20110253T1 (hr) 2011-05-31
AU2008246443A1 (en) 2008-11-13
ES2360841T3 (es) 2011-06-09
CA2686387C (en) 2015-06-30
US20190322648A1 (en) 2019-10-24
IL201921A0 (en) 2010-06-16
BRPI0811275A2 (pt) 2014-12-23
KR101598482B1 (ko) 2016-02-29
CY1111517T1 (el) 2015-08-05
AR066457A1 (es) 2009-08-19
US20210261533A1 (en) 2021-08-26
US8481582B2 (en) 2013-07-09
JP5559677B2 (ja) 2014-07-23
GB0708818D0 (en) 2007-06-13
DK2155731T3 (da) 2011-05-02
EP2155731A1 (en) 2010-02-24
RU2009145270A (ru) 2011-06-20
CN101687858B (zh) 2012-12-26
AU2008246443A8 (en) 2010-01-07
CN101687858A (zh) 2010-03-31
US20130345275A1 (en) 2013-12-26
BRPI0811275B8 (pt) 2021-05-25
IL201921A (en) 2013-11-28
HK1142898A1 (en) 2010-12-17
AU2008246443B2 (en) 2013-07-11
US20100137390A1 (en) 2010-06-03
UA104844C2 (uk) 2014-03-25
TW200918525A (en) 2009-05-01
RU2501796C2 (ru) 2013-12-20
WO2008136695A1 (en) 2008-11-13
ATE499367T1 (de) 2011-03-15
TWI458722B (zh) 2014-11-01
DE602008005141D1 (de) 2011-04-07
EP2155731B1 (en) 2011-02-23
CL2008001321A1 (es) 2008-12-26

Similar Documents

Publication Publication Date Title
NO20093275L (no) 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
NO20083434L (no) Benzamid- og heteroarenderivater
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
NO20062135L (no) Fenylderivater som PPAR-agonister
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
NO20062370L (no) Amidderivater
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
ATE556058T1 (de) 1-(2h)-isochinolonderivat
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
NO20084382L (no) Sykloalkylaminosyrederivater og farmasoytiske sammensetninger derav
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
EA200601235A1 (ru) Производные тиазола
WO2009011285A1 (ja) ヘテロアリールベンゼン化合物
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application